Panelists discuss how the evolving landscape of EGFR-mutated advanced non–small cell lung cancer (NSCLC) treatment, including novel therapies like amivantamab and subcutaneous administration, requires a focus on patient-centered care, shared decision-making, and multidisciplinary collaboration to improve outcomes and manage adverse effects effectively.
